Clinical trials: Non Alcoholic Fatty Liver
Non-alcoholic Fatty Liver Disease
Hepatic Inflammation and Physical Performance in Patients With NASH
The aim of the study is to examine the influence of hepatic inflammation or damage on physical performance (maximal oxygen uptake, VO2max) depending on the histologic state of the liver.
- Trial name
- HELP (NCT02526732)
- Testing
- individual training program
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Priv.-Doz. Dr. J. Schattenberg
Non-alcoholic Fatty Liver Disease (NAFLD, Hypertriglyceridemia
A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
This study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in 2 centres in Sweden to assess the effect of Omega-3 carboxylic acids and fenofibrate on liver fat measured with magnetic…
- Trial name
- NCT02354976
- Testing
- Omega-3 carboxylic acid, Fenofibrate 200mg
- Where
- 4 sites in Sweden
- Volunteers
- 78 people
- Sponsor
- AstraZeneca
Obesity, Obesity, Abdominal
Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD
This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine in reducing visceral and liver adipose tissue among individuals with obesity and non-alcoholic fatty liver disease (NAFLD) in…
- Conditions
- Obesity, Obesity, Abdominal, NAFLD
- Trial name
- BRAVO (NCT05647915)
- Testing
- Berberine plus lifestyle intervention
- Where
- China
- Volunteers
- 337 people
- Sponsor
- China National Center for Cardiovascular Diseases
NAFLD, Cardiovascular Diseases
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world. NAFLD is associated with a lot of comorbidity, such as diabetes, metabolic syndrome, coronary heart disease and chronic…
- Trial name
- NCT03534908
- Where
- China
- Volunteers
- 5,000,000 people, healthy volunteers welcome
- Sponsor
- Wuhan University
NAFLD, Non Alcoholic Steatohepatitis (NASH)
DHA and Vitamin D in Children With Biopsy-proven NAFLD
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children.
- Trial name
- VitD_DHA (NCT02098317)
- Testing
- DHA plus Vitamin D
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease
A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
This study is looking at the effect of semaglutide on subjects with nonalcoholic fatty liver disease.This study is comparing the change in early stages of scar tissue in the liver and fat deposition in the liver in people taking…
- Trial name
- NCT03357380
- Testing
- Semaglutide
- Where
- 2 sites in Germany
- Volunteers
- 67 people
- Sponsor
- Novo Nordisk A/S
Non-alcoholic Fatty Liver Disease
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
This is a multi-center, double blind, parallel group placebo controlled randomised trial designed to determine the safety and efficacy of a Standardised Extract of Phyllanthus Niruri (EPN 797) HEPAR-P capsule for the treatment of…
- Trial name
- Hepar-P (NCT01680003)
- Testing
- Hepar-P
- Where
- 5 sites in Malaysia
- Volunteers
- 50 people
- Sponsor
- Nova Laboratories Sdn Bhd
Healthy
31P Magnetic Resonance Spectroscopy Fructose Study
The purpose of this study is to determine the effects of an oral fructose challenge on liver adenosine triphosphate (ATP) reserves using 31P magnetic resonance spectroscopy (MRS) as a potential measure measure of liver health.
- Trial name
- 31PMRS_FRU (NCT02217605)
- Testing
- Fructose
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stephen Bawden
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty…
- Trial name
- NCT07527910
- Testing
- ALN-PNP, Tirzepatide
- Where
- 9 sites in United States
- Volunteers
- 204 people
- Sponsor
- Regeneron Pharmaceuticals
Non Alcoholic Fatty Liver Disease
Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment
The aim of the current study is to evaluate the association of fatty liver severity and endothelial function in Non-Alcoholic Fatty Liver Disease (NAFLD) patients and to find the impact of statin treatment compared to usual care…
- Trial name
- NCT01987310
- Testing
- atorvastatin, lifestyle counseling
- Where
- Israel
- Sponsor
- Sheba Medical Center
Steatohepatitis, Nonalcoholic, Steatosis of Liver
Ketogenic Diet in MASLD-related cACLD
The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD.
- Conditions
- Steatohepatitis, Nonalcoholic, Steatosis of Liver, Cirrhosis, Liver
- Trial name
- NCT06537466
- Testing
- Mediterranean diet, Very Low Ketogenic Diet
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo
Insulin Resistance, Prediabetic State
Human Models of Selective Insulin Resistance: Alpelisib, Part I
The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes.
- Conditions
- Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT06354088
- Testing
- Alpelisib 300 mg, [1-13C] sodium acetate, [6,6-2H2] D-glucose
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Columbia University
Non-alcoholic Fatty Liver Disease (NAFLD)
The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients
In this first pilot study, we will examine the effects of acetaminophen dosing in adult patients with NAFLD in comparison to the effects in a healthy control group.
- Trial name
- NCT02194894
- Testing
- Acetaminophen
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Southern California
NASH - Nonalcoholic Steatohepatitis
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve Gastrectomy (VSG) with Iifestyle modification, followed for 12 months.
- Trial name
- NCT03587831
- Testing
- Vertical Sleeve Gastrectomy, Lifestyle Modification Counseling
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Type2 Diabetes, Non-Alcoholic Fatty Liver Disease
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases
- Trial name
- NCT03910361
- Testing
- Evogliptin, Pioglitazone
- Where
- 7 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- Dong-A ST Co., Ltd.
Diabetes Mellitus, Non-alcoholic Fatty Liver Disease
Short Term Intermittent Fasting and Insulin Resistance
The purpose of the study is to determine the effect of intermittent fasting on insulin secretion and insulin sensitivity in skeletal muscle and fat distribution.
- Conditions
- Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Obesity
- Trial name
- IFAST (NCT02420054)
- Testing
- Intermittent fasting, Time control
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Non-Alcoholic Fatty Liver Disease, Obesity
Optimal Exercise Frequency to Reduce Liver Fat in Centrally Obese Adults With Non-Alcoholic Fatty Liver Disease
This study aims to examine the comparative effectiveness of different exercise frequencies (once-a-week vs. thrice-a-week) for reducing liver fat in centrally obese adults with non-alcoholic fatty liver disease (NAFLD), with…
- Trial name
- NCT05741957
- Testing
- Once-a-week Exercise, Thrice-a-week Exercise, Usual Care Control
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- The University of Hong Kong
Non-alcoholic Fatty Liver Disease (NAFLD)
How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?
The hypothesis of this study is that a diet high in sugars will increase abnormalities in blood lipids which are associated with increased cardiovascular disease risk, relative to a diet which is low in sugar.
- Trial name
- CHOT (NCT01790984)
- Testing
- High sugar low starch diet, Low sugar high starch diet
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bruce A. Griffin
Atherosclerosis, Non-alcoholic Fatty Liver Disease
Correlation Between NAFLD, Epicardial Adipose Tissue and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)
Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular…
- Trial name
- NCT01958411
- Where
- South Korea
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Korea University
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug…
- Trial name
- NCT05648214
- Testing
- ALN-PNP
- Where
- 6 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.